Table 1 Clinical characteristics at study entry (n = 194).

Male/female

98/96

Age [years] median [range]

40.5 [13–88]

Clinical remission, n [%]

157 [80.9]

Duration of disease [years] median [range]

7 [0–35]

Observation [days] median period

336 [0–518]

Extent

 Total colitis, n [%]

107 [55.2]

 Left-sided colitis, n [%]

58 [29.9]

 Proctitis, n [%]

26 [13.4]

 Right-sided or segmental colitis, n [%]

3 [1.5]

Clinical course

 Relapse-remittng, n [%]

142 [73.2]

 Chronic continuous, n [%]

7 [3.6]

 First attack, n [%]

45 [23.2]

Hemoglobin [g/dL] median [range]

13.7 [9.2–18.2]

CRP [mg/dL] median [range]

0.0455 [0.005–6.65]

Albumin [g/dL] median [range] (n = 192)

4.4 [2.6–5.1]

Platelet [× 10⁴ μL] median [range]

24.5 [12.4–51.1]

LRG [μg/mL] median [range]

10.9 [5–48.7]

FIT [ng/mL] median [range] (n = 128)

30.5 [20–173910]

pMayo score, median [range]

0 [0–8]

Concomitant medication

 5-ASA

  Oral, n [%]

166 [85.6]

  Enema, n [%]

13 [6.7]

  Suppository, n [%]

26 [13.4]

 Steroids

  Oral, n [%] [range of daily dose]

12 [6.2] [2.5–30]

  Rectal, n [%]

23 [11.9]

 Thiopurine

  AZA, n [%] [range of daily dose]

29 [15.0] [20–100]

  6-MP, n [%] [range of daily dose]

9 [9.6] [10–45]

 Biologics

  Anti-TNF agent, n [%]

23 [11.9]

  Anti-α4β7-integrin, n [%]

14 [7.2]

  Anti-IL-12/23p40 antibody, n [%]

4 [2.1]

 JAK inhibitor, n [%]

9 [4.6]

 Tacrolimus, n [%]

1 [0.5]